We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,370 hedge funds and large institutions have $109B invested in Bristol-Myers Squibb in 2021 Q2 according to their latest regulatory filings, with 146 funds opening new positions, 961 increasing their positions, 955 reducing their positions, and 112 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more call options, than puts

Call options by funds: $1.47B | Put options by funds: $1.06B

30% more first-time investments, than exits

New positions opened: 146 | Existing positions closed: 112

6% more capital invested

Capital invested by funds: $102B → $109B (+$6.21B)

3% more funds holding in top 10

Funds holding in top 10: 7072 (+2)

1% more repeat investments, than reductions

Existing positions increased: 961 | Existing positions reduced: 955

0.22% more ownership

Funds ownership: 73%73.22% (+0.22%)

0% more funds holding

Funds holding: 2,3692,370 (+1)

Holders
2,370
Holders Change
+1
Holders Change %
+0.04%
% of All Funds
41.25%
Holding in Top 10
72
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+2.86%
% of All Funds
1.25%
New
146
Increased
961
Reduced
955
Closed
112
Calls
$1.47B
Puts
$1.06B
Net Calls
+$411M
Net Calls Change
+$299M
Name Holding Trade Value Shares
Change
Change in
Stake
NPF
326
Norris Perne & French
Michigan
$18.2M +$299K +4,591 +2%
PI
327
PEAK6 Investments
Illinois
$18.2M -$4.4M -67,467 -20%
E
328
Ergoteles
New York
$18.2M -$5.24M -80,309 -23%
MLICM
329
Metropolitan Life Insurance Company (MetLife)
New York
$18M -$3.16M -48,403 -15%
CA
330
Cullinan Associates
Kentucky
$17.9M +$1.01M +15,534 +6%
CM
331
Capital Management
Virginia
$17.8M -$795K -12,196 -4%
DILIC
332
Dai-ichi Life Insurance Company
Japan
$17.7M +$1.44M +22,160 +9%
CAM
333
Close Asset Management
United Kingdom
$17.7M +$450K +6,906 +3%
SCA
334
Stonebridge Capital Advisors
Minnesota
$17.4M +$8.97M +137,545 +106%
SAM
335
Shell Asset Management
Netherlands
$17.3M -$1.59M -24,435 -9%
UH
336
Unigestion Holding
Switzerland
$17.3M -$28.7M -440,577 -63%
NAM
337
Nissay Asset Management
Japan
$17.1M +$364K +5,587 +2%
Mirae Asset Global Investments
338
Mirae Asset Global Investments
South Korea
$17M +$2.22M +33,972 +15%
HIMCH
339
Hartford Investment Management Co (HIMCO)
Connecticut
$16.9M -$284K -4,348 -2%
NGM
340
North Growth Management
British Columbia, Canada
$16.9M +$1.3M +20,000 +9%
CIP
341
Chartwell Investment Partners
Pennsylvania
$16.8M -$987K -15,143 -6%
GI
342
Gradient Investments
Minnesota
$16.8M +$497K +7,624 +3%
ECM
343
Evergreen Capital Management
Washington
$16.7M +$536K +8,214 +3%
TAF
344
Tredje AP-fonden
Sweden
$16.5M
OSAM
345
O'Shaughnessy Asset Management
Connecticut
$16.4M +$14.2M +217,217 +788%
IIM
346
Intact Investment Management
Quebec, Canada
$15.9M
CAPTRUST Financial Advisors
347
CAPTRUST Financial Advisors
North Carolina
$15.8M -$323K -4,949 -2%
DDPIC
348
Deroy & Devereaux Private Investment Counsel
Michigan
$15.8M +$3.39K +52 +0%
SYBT
349
Stock Yards Bank & Trust
Kentucky
$15.7M +$331K +5,078 +2%
CFB
350
Cullen/Frost Bankers
Texas
$15.6M +$183K +2,810 +1%

BMY Hedge Fund Activity: Q2 2021 in Review

2,370 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2021, worth a combined $109B — up 6.1% from $102B a quarter earlier.

Buyers outnumbered sellers: 146 funds opened new BMY positions and 112 closed out — a net gain of 34 holders — while 961 added to existing stakes and 955 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $582M. The largest seller was Janus Henderson Group, cutting an estimated $444M.

  • 2,370 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2021, up from 2,369 in Q1 2021.
  • Funds reported $109B of Bristol-Myers Squibb stock for Q2 2021, up 6.1% quarter-over-quarter.
  • 146 funds opened new Bristol-Myers Squibb positions in Q2 2021 and 112 closed out, a net change of +34 holders.
  • The largest Bristol-Myers Squibb buyer in Q2 2021 was Fidelity Investments, an estimated $582M added.
  • The largest Bristol-Myers Squibb seller in Q2 2021 was Janus Henderson Group, an estimated $444M sold.

Based on aggregated 13F filings for Q2 2021.